This HTML5 document contains 99 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n17http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01221/identifier/chemspider/
n31http://linked.opendata.cz/resource/drugbank/drug/DB01221/identifier/chebi/
n14http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/mesh/concept/
n12http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/dosage/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01221/identifier/pharmgkb/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01221/identifier/wikipedia/
n21http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB01221/identifier/kegg-compound/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01221/identifier/bindingdb/
n30http://linked.opendata.cz/resource/drugbank/drug/DB01221/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n27http://linked.opendata.cz/resource/drugbank/drug/DB01221/identifier/pubchem-substance/
n29http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01221/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01221/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n26http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01221/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01221
rdf:type
n5:Drug
n5:description
A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. [PubChem]
n5:dosage
n18:271B58DE-363D-11E5-9242-09173F13E4C5 n18:271B58DF-363D-11E5-9242-09173F13E4C5 n18:271B58E0-363D-11E5-9242-09173F13E4C5 n18:271B58D9-363D-11E5-9242-09173F13E4C5 n18:271B58DA-363D-11E5-9242-09173F13E4C5 n18:271B58DB-363D-11E5-9242-09173F13E4C5 n18:271B58DC-363D-11E5-9242-09173F13E4C5 n18:271B58DD-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Harrison NL, Simmonds MA: Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol. 1985 Feb;84(2):381-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2858237 # Bergman SA: Ketamine: review of its pharmacology and its use in pediatric anesthesia. Anesth Prog. 1999 Winter;46(1):10-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10551055 # Bonanno FG: Ketamine in war/tropical surgery (a final tribute to the racemic mixture). Injury. 2002 May;33(4):323-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12091028 # Lankenau SE, Sanders B, Bloom JJ, Hathazi D, Alarcon E, Tortu S, Clatts MC: First injection of ketamine among young injection drug users (IDUs) in three U.S. cities. Drug Alcohol Depend. 2007 Mar 16;87(2-3):183-93. Epub 2006 Sep 18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16979848 # Reboso Morales JA, Gonzalez Miranda F: [Ketamine] Rev Esp Anestesiol Reanim. 1999 Mar;46(3):111-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10228376
n5:group
approved
n5:halfLife
2.5-3 hours.
n5:indication
For use as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation.
owl:sameAs
n21:DB01221 n29:DB01221
dcterms:title
Ketamine
adms:identifier
n4:3689 n8:50044140 n9:C07525 n10:61570-581-10 n11:DB01221 n22:D08098 n23:Ketamine n27:46508295 n28:PA450144 n30:3821 n31:6121
n5:mechanismOfAction
Ketamine has several clinically useful properties, including analgesia and less cardiorespiratory depressant effects than other anaesthetic agents, it also causes some stimulation of the cardiocascular system. Ketamine has been reported to produce general as well as local anaesthesia. It interacts with N-methyl-D-aspartate (NMDA) receptors, opioid receptors, monoaminergic receptors, muscarinic receptors and voltage sensitive Ca ion channels. Unlike other general anaesthetic agents, ketamine does not interact with GABA receptors.
n5:packager
n12:271B58C6-363D-11E5-9242-09173F13E4C5 n12:271B58CD-363D-11E5-9242-09173F13E4C5 n12:271B58CE-363D-11E5-9242-09173F13E4C5 n12:271B58CB-363D-11E5-9242-09173F13E4C5 n12:271B58CC-363D-11E5-9242-09173F13E4C5 n12:271B58C9-363D-11E5-9242-09173F13E4C5 n12:271B58CA-363D-11E5-9242-09173F13E4C5 n12:271B58C7-363D-11E5-9242-09173F13E4C5 n12:271B58C8-363D-11E5-9242-09173F13E4C5
n5:synonym
Special k Ketamina (±)-ketamine 2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone 2-(methylamino)-2-(2-chlorophenyl)cyclohexanone NMDA KETAMINE Ketaminum DL-ketamine (+-)-Ketamine
n13:hasAHFSCode
n14:28-04-00 n14:28-04-92
n5:salt
n5:synthesisReference
John A. Flores, Kenton L. Crowley, "Process for the preparation of ketamine ointment." U.S. Patent US5817699, issued June, 1995.
n24:hasConcept
n25:M0011982
foaf:page
n17:ketamine.htm n26:ketamine.html
n5:IUPAC-Name
n7:271B58E5-363D-11E5-9242-09173F13E4C5
n5:InChI
n7:271B58EB-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n7:271B58EA-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n7:271B58E7-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n7:271B58E8-363D-11E5-9242-09173F13E4C5
n5:SMILES
n7:271B58E9-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n7:271B58E3-363D-11E5-9242-09173F13E4C5
n5:logP
n7:271B58E4-363D-11E5-9242-09173F13E4C5 n7:271B58E1-363D-11E5-9242-09173F13E4C5 n7:271B58FC-363D-11E5-9242-09173F13E4C5
n5:logS
n7:271B58E2-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n19:N01AX03
n5:H-Bond-Acceptor-Count
n7:271B58F1-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n7:271B58F2-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n7:271B58EC-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n7:271B58ED-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n7:271B58EF-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n7:271B58EE-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n7:271B58F0-363D-11E5-9242-09173F13E4C5
n5:absorption
Rapidly absorbed following parenteral administration.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
6740-88-1
n5:category
n5:containedIn
n6:271B58D0-363D-11E5-9242-09173F13E4C5 n6:271B58D7-363D-11E5-9242-09173F13E4C5 n6:271B58D8-363D-11E5-9242-09173F13E4C5 n6:271B58D5-363D-11E5-9242-09173F13E4C5 n6:271B58D6-363D-11E5-9242-09173F13E4C5 n6:271B58D3-363D-11E5-9242-09173F13E4C5 n6:271B58D4-363D-11E5-9242-09173F13E4C5 n6:271B58D1-363D-11E5-9242-09173F13E4C5 n6:271B58D2-363D-11E5-9242-09173F13E4C5 n6:271B58CF-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n7:271B58F7-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n7:271B58F9-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n7:271B58FA-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n7:271B58FB-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n7:271B58F6-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n7:271B58F5-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n7:271B58F8-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n7:271B58E6-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n7:271B58F3-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n7:271B58F4-363D-11E5-9242-09173F13E4C5